Prosecution Insights
Last updated: April 19, 2026

Examiner: GHALI, ISIS A D

Tech Center 1600 • Art Units: 1611

This examiner grants 28% of resolved cases

Performance Statistics

27.7%
Allow Rate
-32.3% vs TC avg
898
Total Applications
+41.0%
Interview Lift
1686
Avg Prosecution Days
Based on 838 resolved cases, 2023–2026

Rejection Statute Breakdown

0.8%
§101 Eligibility
8.5%
§102 Novelty
50.2%
§103 Obviousness
24.6%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17798531 OMECAMTIV MECARBIL TABLET Final Rejection Amgen Inc.
17503762 MULTI-PHASE ORAL COMPOSITION FOR DELIVERING ORAL CARE ACTIVE AGENTS Non-Final OA The Procter & Gamble Company
17268129 CORE BODY TEMPERATURE REDUCING AGENT, FOOD PRODUCT, AND SLEEP IMPROVING AGENT Final Rejection JAPAN TOBACCO INC.
17840276 METHODS TO ENHANCE BIOAVAVAILABILITY OF ORGANIC SMALL MOLECULES AND DEPOSITED FILMS MADE THEREFROM Final Rejection THE REGENTS OF THE UNIVERSITY OF MICHIGAN
17479614 CHEWABLE GEL PRODUCTS FOR ACTIVE PHARMACEUTICAL INGREDIENTS Final Rejection Bayer HealthCare LLC
15301281 CONTRACEPTIVE AND RELATED DEVICE Non-Final OA POLY-MED, INC.
18265324 PERSONAL CARE COMPOSITION Final Rejection Conopco, Inc., d/b/a UNILEVER
17713803 FABRIC COMPOSITIONS COMPRISING ATTACHED ZEOLITE AND/OR A ZEOLITE/PECTIN COMPLEX Non-Final OA Virginia Commonwealth University
18709906 HEIGHT-ADJUSTABLE SPRINKLER Non-Final OA BTGIN CO., LTD.
18283379 COSMETIC Non-Final OA SHISEIDO COMPANY, LTD.
17854688 DISRUPTED CARTILAGE PRODUCTS Final Rejection OSIRIS THERAPEUTICS, INC.
18144365 ANHYDROUS HYDROCOLLOID MATRIX COMPRISING HOMOGENEOUSLY DISTRIBUTED ENCAPSULATED THERAPEUTIC AGENTS Non-Final OA Peace Out, LLC
18339310 THERAPEUTIC USE OF CHARDONNAY SEED PRODUCTS Non-Final OA The United States of America, as represented by the Secretary of Agriculture
18398021 SUSPENSION COMPOSITIONS OF MULTI-TARGET INHIBITORS Final Rejection AIVIVA BIOPHARMA, INC.
16585630 METHODS AND COMPOSITIONS FOR ENHANCING HEALTH Non-Final OA Ojai Energetics PBC
18239557 Dermal Patch for Transdermal Administration of Ghrelin Pathway Blocker Non-Final OA Resarcion LLC
18024788 PREPARATIONS CONTAINING MITRAGYNE EXTRACT OR ITS ISOLATED ALKALOIDS AND CANNABIS EXTRACT OR ITS ISOLATED CANNABINOIDS, AND COSMETIC AND/OR PHARMACEUTICAL USE THEREOF Non-Final OA Herba Invest Europe DOO
16968710 HAEMOSTATIC MATERIAL Final Rejection MEDTRADE PRODUCTS LIMITED
17912278 CANNABINOID MEDICAL CARRIER Non-Final OA New York Medical College
18015952 FORMULATION PRODUCT Non-Final OA Nutriigen Ltd.
17809174 CORONA DISCHARGE TREATED TRANSDERMAL DELIVERY SYSTEM Final Rejection Corium, LLC
18046551 Drug Eluting Foams and the Production Thereof Non-Final OA Polyganics IP B.V.
17529591 Drug Eluting Foams and the Production Thereof Final Rejection Polyganics IP B.V.
16382652 Drug Eluting Foams and the Production Thereof Final Rejection Polyganics IP B.V.
17964270 TRANSDERMAL DEVICE COMPRISING IBUPROFEN PRODRUG MOLECULES Non-Final OA Remedy Diagnostics LLC
17907373 METHOD FOR OBTAINING A BOTANICAL EXTRACT Final Rejection EUROMED, S.A.
17694312 TOPICAL DRUG DELIVERY DEVICES AND METHODS OF USE Final Rejection MJS Solutions, LLC
17401598 TRANSDERMAL PHARMACEUTICAL FORMULATIONS OF NABILONE ALONE AND IN COMBINATION WITH CANNABINOIDS Non-Final OA Pike Therapeutics Inc.
17331119 INTRAVAGINAL RING DEVICES Final Rejection DARÉ BIOSCIENCE, INC.
16678466 INHALABLE HEMODYNAMIC AGENTS AND METHODS OF USING THE SAME Final Rejection TRUIST BANK, AS ADMINISTRATIVE AGENT

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month